Overview

Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

Status:
NOT_YET_RECRUITING

Trial end date:
2031-12-01

Target enrollment:

Participant gender:

Summary

This is a randomized, controlled, multi-center phase II/III study. All patients are resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of perioperative Cadonilimab combined with neoadjuvant chemotherapy versus neoadjuvant chemotherapy in patients with resectable ESCC.

Phase:

PHASE2

Details

Lead Sponsor:

Akeso

Treatments:

Cisplatin
Paclitaxel